Cat. No. 1980
Chemical Name: N2-[[2-(2-Naphthalenyl)-1H-benz[g]i
Biological ActivityPotent and selective somatostatin sst5 receptor agonist. Ki values are 0.4, 3.3, 52, 64 and 82 nM for cloned human sst5, sst1, sst2, sst3 and sst4 receptors respectively. Inhibits growth hormone release from rat pituitary cells (EC50 = 3.1 nM) and insulin release from mouse pancreatic islets (EC50 = 0.3 nM) in vitro.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Rohrer and Schaeffer (2000) Identification and characterization of subtype selective somatostatin receptor agonists. J.Physiol.Paris 94 211. PMID: 11087999.
Strowski et al (2000) Somatostatin inhibits insulin and glucagon secretion via two receptor subtypes: An in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology 141 111. PMID: 10614629.
Rohrer et al (1998) Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 282 737. PMID: 9784130.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses L-817,818 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: L-817,818, supplier, Potent, selective, sst5, agonists, Receptors, Somatostatin, L817818, Tocris Bioscience, Somatostatin (sst) Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
FPR2 (lipoxin A4 receptor) agonistAmylin (rat)
Potent endogenous peptide agonist for amylin, calcitonin, CGRP and adrenomedullin receptorsCalcitonin (human)
Endogenous calcitonin receptor agonist; inhibits bone resorptionSpexin
Potent GAL2/3 agonist; exhibits anxiolytic effects in vivoMM 54
Potent apelin receptor antagonistMSG 606
Potent human MC1 receptor antagonist; also MC3 and MC5 partial agonist
March 18 - 22, 2017
Little Rock, ARK, USA